双歧杆菌三联活菌联合四联疗法治疗幽门螺杆菌阳性胃食管反流患者的效果

Effects of Bifidobacterium triple viable bacteria Combined with quadruple therapy on Helicobacter pylori positive gastroesophageal reflux

目的:观察双歧杆菌三联活菌联合四联疗法治疗幽门螺杆菌(Hp)阳性胃食管反流患者的效果。方法:选取2020年6月至2023年4月该院收治的200例Hp阳性胃食管反流患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各100例。对照组采用四联疗法治疗,研究组在对照组基础上联合双歧杆菌三联活菌治疗,比较两组临床疗效、Hp根除率、治疗前后临床症状评分、胃功能[胃蛋白酶原I(PGI)、胃泌素-17(G-17)]水平和食管括约肌压力[上食管括约肌(UES)、下食管括约肌(LES)静息压]水平及不良反应发生率。结果:研究组治疗总有效率为95.00%(95/100),高于对照组的85.00%(85/100),差异有统计学意义(P<0.05);研究组Hp根除率为93.00%(93/100),高于对照组的82.00%(82/100),差异有统计学意义(P<0.05);治疗后,两组临床症状评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组PGI、G-17水平和UES、LES静息压均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双歧杆菌三联活菌联合四联疗法治疗Hp阳性胃食管反流患者,可提高临床疗效和Hp根除率,改善胃功能和食管括约肌压力,效果优于单纯四联疗法治疗。

Objective:To observe effects of Bifidobacterium triple viable bacteria combined with quadruple therapy in treatment of patients with Helicobacter pylori(Hp)positive gastroesophageal reflux.Methods:A prospective study was conducted on 200 patients with Hp-positive gastroesophageal reflux admitted to the hospital from June 2020 to April 2023.According to the random number table method,they were divided into control group and study group,100 cases in each group.The control group was treated with quadruple therapy,while the study group was treated with Bifidobacterium triple viable bacteria on the basis of that of the control group.The clinical efficacy,the Hp eradication rate,the clinical symptom scores before and after the treatment,the gastric function[pepsinogen I(PGI),gastrin-17(G-17)]levels,the esophageal sphincter pressure[upper esophageal sphincter(UES)and lower esophageal sphincter(LES)resting pressure]level,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 95.00%(95/100),which was higher than 85.00%(85/100)in the control group,and the difference was statistically significant(P<0.05).The Hp eradication rate of the study group was 93.00%(93/100),which was higher than 82.00%(82/100)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the clinical symptom scores of the two groups were lower than those before the treatment,that in the study group was lower than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of PGI,G-17,and UES and LES resting pressure in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bifidobacterium triple viable bacteria combined with quadruple therapy in the treatment of the Hp-positive gastroesophageal reflux patients can improve the clinical efficacy and the Hp eradication rate and improve the gastric function and the esophageal sphincter pressure.Moreover,it is superior to single quadruple therapy.